510(k) device
Modification to Mammaprint
Agendia · Classifier, Prognostic, Recurrence Risk Assessment, Rna Gene Expression, Breast Cancer (NYI, Class II) · First FDA decision Jul 21, 2008, newest Dec 11, 2009Breast cancer
Last checked: Nov 21, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
510(k) pathway
Device trials
0
Naming "Modification to Mammaprint"
MAUDE reports
0
Brand "Modification to Mammaprint", since 2015
PubMed studies
0
Mentioning "Modification to Mammaprint"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Modification to Mammaprint
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
K081092 · Decided Dec 11, 2009 · 603 days after receipt
Device type: Classifier, Prognostic, Recurrence Risk Assessment, Rna Gene Expression, Breast Cancer (NYI) · Laboratory Medicine & Pathology
1 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- MolDX: Prognostic and Predictive Molecular Classifiers for Bladder CancerLocal determinationIn effectL38586CGS Administrators, LLCUpdated May 11, 2026
- MolDX: Prognostic and Predictive Molecular Classifiers for Bladder CancerLocal determinationIn effectL38684WPS Insurance CorporationUpdated Apr 10, 2026
- MolDX: Prognostic and Predictive Molecular Classifiers for Bladder CancerLocal determinationIn effectL38647Noridian Healthcare Solutions, LLCUpdated Apr 7, 2026
- MolDX: Prognostic and Predictive Molecular Classifiers for Bladder CancerLocal determinationIn effectL38576Palmetto GBAUpdated Apr 7, 2026
- MolDX: EndoPredict Breast Cancer Gene Expression TestLocal determinationIn effectL37356CGS Administrators, LLCUpdated Apr 6, 2026
- MolDX: Breast Cancer Index® (BCI) Gene Expression TestLocal determinationIn effectL37913WPS Insurance CorporationUpdated Feb 20, 2026
- MolDX: Breast Cancer Index® (BCI) Gene Expression TestLocal determinationIn effectL37822Noridian Healthcare Solutions, LLCUpdated Jan 12, 2026
- MolDX: EndoPredict® Breast Cancer Gene Expression TestLocal determinationIn effectL37295Noridian Healthcare Solutions, LLCUpdated Jan 12, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Modification to Mammaprint", any status and sponsor, newest update first.
No registered device study names "Modification to Mammaprint".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Modification to Mammaprint", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code NYI
1 reports: 0 malfunction, 1 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-1321-2010 · Started Mar 3, 2010 · Posted by FDA Apr 12, 2010
Reason given: Over a period of about 6 months in about 15% of results provided Agendia has been "over reporting" the chance of metastasis risk being 29% risk of recurrence instead of 10% risk. This over reporting of risk did not cause direct injury to patients. However, if used by physicians as the sole basis for decision-making,...
Cause as FDA categorized it: Other · Device type: Classifier, Prognostic, Recurrence Risk Assessment, Rna Gene Expression, Breast Cancer (NYI)
Published research
The most relevant PubMed records for "Modification to Mammaprint"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code NYI.
- MammaPrintAgendia, Inc. · De Novo 2020
- Prosigna Breast Cancer Prognostic Gene Signature AssayNanostring Technologies, Inc. · 510(k) 2014
- MammaPrint FFPE NGS KitAgendia, Inc. · 510(k) 2022
- Mammaprint FfpeAgendia · 510(k) 2015
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.